SLC2A3 and neoplasm: The upregulation of the novel doxorubicin importer SLC2A3 would directly increase the uptake of doxorubicin in K562 and 293T cells (Fig. 5C and Supplementary Fig. 6), and result in the better killing of these tumor cells.